TerumoTERUMO CORPORATION4543東証プライム精密機器FY ending Mar 2026, consolidated, IFRS

Terumo FY ending Mar 2026 results

About 60% of Terumo's sales come from Cardiac and Vascular Company, with Blood and Cell Technologies Company and Medical Care Solutions Company making up much of the rest.

Out of every ¥100 of sales, about ¥16 is left as operating profit.

Revenue changed +9.2% from the prior year, operating profit +11.8%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +9.2% · profit +11.8%, calculated from disclosed figures.

Operating leverage: 1.28× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue: +9.2%¥1.04T → ¥1.13T
Gross profit: +6.1%¥560.7B → ¥594.7B
Operating income: +11.8%¥157.7B → ¥176.3B
Net income attributable to owners: +16.2%¥117B → ¥135.9B
Operating cash flow: +9.5%¥210.8B → ¥230.9B
Free cash flow: +0.4%¥128.4B → ¥128.9B

Results at a glance

Revenue for the FY ending Mar 2026 was ¥1.13T, up 9.2% from ¥1.04T.
Profit grew faster than sales: operating income rose 11.8% to ¥176.3B and net income rose 16.2% to ¥135.9B.
Gross profit grew more slowly, up 6.1% to ¥594.7B.
Operating cash flow rose 9.5% to ¥230.9B, while free cash flow was nearly flat at ¥128.9B, up 0.4%.

What drove the change

Demand for medical care kept growing worldwide, and the main businesses grew, led by the Americas.
Outside Japan, catheter access products and the plasma business in North America lifted sales.
US tariff policy weighed on gross profit, but higher sales still pushed it up.

Things to watch

The company expects supply chain disruption and high raw material prices to continue.
Geopolitical risk, including the situation in the Middle East, has made the outlook uncertain.
The forecast already includes an estimated impact from US tariffs, based on the company's own assumptions.

Annual Securities Report, 111th term / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Terumo sells, how much goes where, and how much is kept.

FY ending Mar 2026

Cost of sales: ¥47
SG&A: ¥36
Other costs: ¥1
Operating profit: ¥16
Net profit kept: ¥12

Annual margin trends

Gross margin52.5%

Operating margin15.6%

Net margin12.0%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Cardiac and Vascular Company¥676.4B
60%
Op. margin 24.2%Industry: Medical Devices
Blood and Cell Technologies Company¥231B
20%
Op. margin 14.6%Industry: Medical Devices
Medical Care Solutions Company¥216.1B
19%
Op. margin 10.0%Industry: Medical Devices
Terumo Organ Technologies¥7.99B
1%
Op. margin 20.9%Industry: Medical Devices

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第111期(2025/04/01－2026/03/31)
ID S100YGMG2026-06-23Open
EDINET (FSA Japan)
有価証券報告書－第110期(2024/04/01－2025/03/31)
ID S100VWHX2025-06-23Open
EDINET (FSA Japan)
有価証券報告書－第109期(2023/04/01－2024/03/31)
ID S100TULJ2024-06-27Open
EDINET (FSA Japan)
有価証券報告書－第108期(2022/04/01－2023/03/31)
ID S100R4TX2023-06-28Open
EDINET (FSA Japan)
訂正有価証券報告書－第107期(令和3年4月1日－令和4年3月31日)
ID S100OS1S2022-07-26Open
EDINET (FSA Japan)
有価証券報告書－第106期(令和2年4月1日－令和3年3月31日)
ID S100LLAO2021-06-23Open

Extracted from XBRL: 44 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image